P. Lesbats, A. N. Engelman, and P. Cherepanov, Retroviral DNA integration, Chem Rev, vol.116, pp.12730-57, 2016.

A. Engelman and P. Cherepanov, The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication, PLoS Pathog, vol.4, p.1000046, 2008.

G. A. Sowd, E. Serrao, H. Wang, W. Wang, H. J. Fadel et al., A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin, Proc Natl Acad Sci, vol.113, pp.1054-63, 2016.

P. Cherepanov, G. Maertens, P. Proost, B. Devreese, V. B. Jozef et al., HIV-1 integrase forms stable tetramers and associates with LEDGF/ p75 protein in human cells, J Biol Chem, vol.278, pp.372-81, 2003.

S. Emiliani, A. Mousnier, K. Busschots, M. Maroun, B. Van-maele et al., Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication, J Biol Chem, vol.280, pp.25517-25540, 2005.

F. Christ, A. Voet, A. Marchand, S. Nicolet, B. A. Desimmie et al., Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication, Nat Chem Biol, vol.6, pp.442-450, 2010.

J. J. Kessl, J. N. Koh, Y. Taskent-sezgin, H. Slaughter, A. Feng et al., cooperative mechanism of action of allosteric HIV-1 integrase inhibitors, J Biol Chem, vol.287, pp.16801-16812, 2012.

M. Tsiang, G. S. Jones, A. Niedziela-majka, E. Kan, E. B. Lansdon et al., New class of HIV-1 integrase (IN) inhibitors with a dual mode of action, J Biol Chem, vol.287, pp.21189-203, 2012.

M. Balakrishnan, S. R. Yant, L. Tsai, C. O'sullivan, R. A. Bam et al., Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells, PLoS ONE, vol.8, p.74163, 2013.

C. Fenwick, M. Amad, M. D. Bailey, R. Bethell, M. Bös et al., Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor, Antimicrob Agents Chemother, vol.58, pp.3233-3277, 2014.

A. Sharma, A. Slaughter, N. Jena, L. Feng, J. J. Kessl et al., A new class of multimerization selective inhibitors of HIV-1 integrase, PLoS Pathog, vol.10, p.1004171, 2014.

L. Rouzic, E. Bonnard, D. Chasset, S. Bruneau, J. Chevreuil et al., Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage, Retrovirology, vol.10, p.144, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00914180

F. Christ, S. Shaw, J. Demeulemeester, B. A. Desimmie, A. Marchand et al., Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization, Antimicrob Agents Chemother, vol.56, pp.4365-74, 2012.

B. A. Desimmie, R. Schrijvers, J. Demeulemeester, D. Borrenberghs, C. Weydert et al., LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions, Retrovirology, vol.10, p.57, 2013.

K. A. Jurado, H. Wang, A. Slaughter, L. Feng, J. J. Kessl et al., Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation, Proc Natl Acad Sci, vol.110, pp.8690-8695, 2013.

J. Fontana, K. A. Jurado, N. Cheng, N. L. Ly, J. R. Fuchs et al., Distribution and redistribution of HIV-1 nucleocapsid protein in immature, mature, and integrase-inhibited virions: a role for integrase in maturation, J Virol, vol.89, pp.9765-80, 2015.

J. J. Kessl, S. B. Kutluay, D. Townsend, S. Rebensburg, A. Slaughter et al., HIV-1 integrase binds the viral RNA genome and is essential during virion morphogenesis, Cell, vol.166, p.12, 2016.

L. S. Vranckx, J. Demeulemeester, S. Saleh, A. Boll, G. Vansant et al., LEDGIN-mediated inhibition of Integrase-LEDGF/p75 interaction reduces reactivation of residual latent HIV, EBioMedicine, vol.8, pp.248-64, 2016.

M. P. Girard, S. Osmanov, O. M. Assossou, and M. Kieny, Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review, Vaccine, vol.29, pp.6191-218, 2011.

F. Garcia and J. Routy, Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection, Vaccine, vol.29, pp.6454-63, 2011.

F. Garcia, N. Climent, A. C. Guardo, C. Gil, A. Leon et al., A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication, Sci Transl Med, vol.5, pp.166-168, 2013.

S. Chasset, F. Chevreuil, B. Ledoussal, L. Strat, F. Benarous et al., Inhibitors of viral replication, their process of preparation and their therapeutical uses

N. Van-bel, Y. Van-der-velden, D. Bonnard, L. Rouzic, E. Das et al., The allosteric HIV-1 Integrase inhibitor BI-D affects virion maturation but does not influence packaging of a functional RNA genome, PLoS ONE, vol.9, p.103552, 2014.

A. Rutebemberwa, J. W. Bess, B. Brown, M. Arroyo, M. Eller et al., Evaluation of aldrithiol-2-inactivated preparations of HIV type 1 subtypes A, B, and D as reagents to monitor T cell responses, AIDS Res Hum Retroviruses, vol.23, pp.532-574, 2007.

T. Kodama, D. P. Wooley, Y. M. Naidu, H. W. Kestler, M. D. Daniel et al., Significance of premature stop codons in env of simian immunodeficiency virus, J Virol, vol.63, pp.4709-4723, 1989.

C. Moog, N. Dereuddre-bosquet, J. Teillaud, M. E. Biedma, V. Holl et al., Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques, Mucosal Immunol, vol.7, pp.46-56, 2014.

X. Wu, Z. Yang, Y. Li, C. Hogerkorp, W. R. Schief et al., Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1, Science, vol.329, pp.856-61, 2010.

L. M. Walker, S. K. Phogat, C. Wagner, D. Phung, P. Goss et al., Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target, Science, vol.326, pp.285-294, 2009.

T. Zhou, L. Xu, B. Dey, A. J. Hessell, D. Van-ryk et al., Structural definition of a conserved neutralization epitope on HIV-1 gp120, Nature, vol.445, pp.732-739, 2007.

A. Trkola, M. Purtscher, T. Muster, C. Ballaun, A. Buchacher et al., Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1, J Virol, vol.70, pp.1100-1108, 1996.

T. Muster, F. Steindl, M. Purtscher, A. Trkola, A. Klima et al., A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1, J Virol, vol.67, pp.6642-6649, 1993.

G. Stiegler, R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer et al., A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1, AIDS Res Hum Retroviruses, vol.17, pp.1757-65, 2001.

M. B. Zwick, A. F. Labrijn, M. Wang, C. Spenlehauer, E. O. Saphire et al., Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41, J Virol, vol.75, pp.10892-905, 2001.

V. Lorin and H. Mouquet, Efficient generation of human IgA monoclonal antibodies, J Immunol Methods, vol.422, pp.102-112, 2015.

P. D. Kwong and J. R. Mascola, Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies, Immunity, vol.37, pp.412-437, 2012.

R. Burrer, S. Haessig-einius, A. Aubertin, and C. Moog, Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41, Virology, vol.333, pp.102-115, 2005.

P. N. Nyambi, S. Burda, L. Bastiani, and C. Williams, A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1, J Immunol Methods, vol.253, pp.253-62, 2001.

N. Climent, S. Guerra, F. García, C. Rovira, L. Miralles et al., Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals, PLoS ONE, vol.6, p.19644, 2011.

K. Peden, M. Emerman, and L. Montagnier, Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI, Virology, vol.185, pp.661-72, 1991.

W. Zhang, S. Cao, J. L. Martin, J. D. Mueller, and L. M. Mansky, Morphology and ultrastructure of retrovirus particles, AIMS Biophys, vol.2, pp.343-69, 2015.

A. Bender, L. K. Bui, M. A. Feldman, M. Larsson, and N. Bhardwaj, Inactivated influenza virus, when presented on dendritic cells, elicits human CD8 + cytolytic T cell responses, J Exp Med, vol.182, pp.1663-71, 1995.

M. Larsson, J. Fonteneau, M. Lirvall, P. Haslett, J. D. Lifson et al., Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus, AIDS, vol.16, pp.1319-1348, 2002.

F. Buseyne, L. Gall, S. Boccaccio, C. Abastado, J. P. Lifson et al., MHC-I-restricted presentation of HIV-1 virion antigens without viral replication, Nat Med, vol.7, pp.344-353, 2001.
URL : https://hal.archives-ouvertes.fr/pasteur-01372734

A. C. Guardo, C. Alvarez-fernández, H. Arberas, J. García-pérez, F. García et al., Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individuals, PLoS ONE, vol.8, p.58927, 2013.

T. Mesplède and M. A. Wainberg, Will LEDGIN molecules be able to play a role in a cure for HIV infection?, EBioMedicine, vol.8, pp.14-19, 2016.